IBD: Ulcerative Colitis
IBD: Switching from a Biologic to a Biosimilar
Updated March 20201
Having to change any kind of medication can be very stressful. While CDHF believes in patient-physician choice, we acknowledge political policy decisions and our organization is committed to providing clear and unbiased information and resources for patients. Both biologics and biosimilars have gone through rigorous standards for authorization by Health Canada, to which both have been found safe and effective for use in Inflammatory Bowel Disease (IBD). Watch this video to learn more about switching from a biologic to a biosimilar.
Related Articles
This empowering session reviewed the basics of IBD, outlined the benefits and risks of medications used to treat ulcerative colitis and Crohn’s disease and answered the […]
Helping inflammatory bowel disease (IBD) patients best understand transitioning/switching from a reference biologic to a biosimilar.
CDHF is Canada’s trusted source for timely information on the BC Biosimilars Initiative What’s Changing? Since its launch, the Initiative has successfully switched many PharmaCare patients […]